Brief: Prelude Therapeutics Announces Pricing Of Initial Public Offering
25/09/2020 02:28
Sept 24 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC
OFFERING
* PRELUDE THERAPEUTICS INCORPORATED - PRICING OF ITS INITIAL
PUBLIC OFFERING OF 8.3 MILLION SHARES OF COMMON STOCK AT $19.00
PER SHARE
* PRELUDE THERAPEUTICS INC - SHARES ARE EXPECTED TO BEGIN
TRADING
ON NASDAQ GLOBAL SELECT MARKET ON SEPTEMBER 25, 2020 UNDER
TICKER SYMBOL "PRLD"
Source text for Eikon: ID:nGNX68H5y1
Further company coverage: PRLD.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview